Gilead Sciences Expands Autoimmune Pipeline with Acquisition of Ouro Medicines
Gilead Sciences Moves to Acquire Ouro Medicines, Strengthening Its Autoimmune and Inflammation Pipeline with Innovative T-Cell Engager Technology Gilead Sciences has announced a major strategic step to expand its presence in the autoimmune disease space through a definitive agreement to…
Biocytok–Moonlight Bio Partner on Human Antibody Cell Therapy
Biocytok and Moonlight Bio Collaborate to Advance Cell Therapy with Fully Human Antibody Library Biocytogen (Beijing) Pharmaceutical Technology a globally focused biotechnology company known for its innovative platforms in drug discovery and development, has entered into a strategic collaboration agreement…
Bristol Myers Squibb Advances Hodgkin Lymphoma Care Expanded Opdivo Approvals
Bristol Myers Squibb gains U.S. Food and Drug Administration and European Medicines Agency approvals, expanding Opdivo use in Hodgkin lymphoma Bristol Myers Squibb has announced significant regulatory milestones that mark a major advancement in the treatment landscape for classical Hodgkin…
Incyte Highlights Late-Breaking HS Data at AAD 2026
Incyte Showcases HS Data at AAD 2026 Incyte has announced that it will present a comprehensive set of new clinical data from its Inflammation and Autoimmunity (IAI) portfolio at the American Academy of Dermatology Annual Meeting 2026, scheduled to take…
Curi Bio & Battelle Partner to Advance Neuromuscular Drug Testing
Strategic Collaboration to Accelerate Human-Relevant Neuromuscular Testing Curi Bio and Battelle have announced a strategic collaboration aimed at transforming the field of neuromuscular pharmacology through the accelerated adoption of New Approach Methods (NAMs). This partnership represents a significant step forward…
AmeriPro Health Teams Up with Orion Talent to Boost Veteran Hiring in EMS Operations
AmeriPro Health Partners with Orion Talent to Boost Veteran Hiring in EMS AmeriPro Health has taken a significant step in strengthening its workforce and expanding its national footprint by announcing a strategic partnership with Orion Talent. This collaboration is focused…
Aptar’s Unidose Nasal Powder System Featured in Phase II Study of ENA’s INNA-051 Nasal Spray
Aptar’s Introduction to INNA-051 Investigational Nasal Spray AptarGroup a global leader in drug delivery, dosing, and protection technologies, has announced the use of its Unidose (UDS) Powder Nasal Spray System in a Phase II clinical study being conducted by ENA…
Innovive Health Expands Behavioral Health Home Care Services in Colorado
Innovive Health Expands Behavioral Home Healthcare Services Across Key Regions in Colorado to Support Vulnerable Populations Innovive Health, a leading provider of specialized home healthcare services for patients with complex behavioral health conditions and coexisting medical needs, has announced a…
Kardigan Showcases Late-Stage Precision Cardiovascular Portfolio at ACC.26
Kardigan to Present Late-Stage Cardiovascular Pipeline and AI-Driven Insights at ACC.26 Kardigan, a company focused on transforming heart health through innovative drug development, has announced multiple presentations at the ACC.26. The event will take place from March 28 to March…
Exact Sciences to Showcase MRD and Multi-Cancer Detection Data at AACR 2026
Exact Sciences Highlights Advances in MRD and Multi-Cancer Early Detection at AACR 2026 Exact Sciences Corp. is set to present significant new data at the AACR Annual Meeting 2026, underscoring its continued leadership in cancer diagnostics and precision oncology. The…
Fulgent Genetics completes acquisition of Bako Diagnostics and StrataDx
Fulgent Genetics finalizes $56.9 million deal to expand pathology and dermatopathology capabilities with Bako Diagnostics and StrataDx Fulgent Genetics, Inc., a technology-driven company known for its strong laboratory services platform and growing therapeutic development efforts, has officially completed its previously…
Aarvik Therapeutics Presents New ADC Molecules at AACR 2026
Aarvik Therapeutics Unveils Novel ADCs at AACR 2026 Aarvik Therapeutics, a biotechnology company focused on advancing antibody-drug conjugate (ADC) technologies, has announced its participation in the AACR Annual Meeting 2026, where it will present multiple scientific findings highlighting its innovative…